Statement Of Cash Flows [Abstract]

BerGenBio - Filing #2542730

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for interest income
3,055,000 NOK
2,949,000 NOK
Adjustments for increase (decrease) in trade and other payables
31,809,000 NOK
13,641,000 NOK
Adjustments for depreciation expense
223,000 NOK
883,000 NOK
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
36,971,000 NOK
7,000 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.